Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Sunday, Allogene Reports 31% Confirmed Response Rate With ALLO-316 In CD70-High RCC Patients At ASCO, With Durable Remissions And Manageable Safety

Author: Benzinga Newsdesk | June 02, 2025 02:57am

Data Highlights Transformative Promise of CAR T in Solid Tumors
Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC
- A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate
- Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months
Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform
Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy

Posted In: ALLO